Picture of Takeda Pharmaceutical Co logo

TAK Takeda Pharmaceutical Co News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareConservativeLarge CapSuper Stock

REG - Societe Generale SA Takeda Pharma.Co.Ltd - Form 8.3 - Takeda Pharmaceutical Co Ltd





 




RNS Number : 5810A
Societe Generale SA
12 September 2018
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1.         KEY INFORMATION

 

(a) Full name of discloser:

Société Générale S.A.

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

     The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.

 

 

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

     Use a separate form for each offeror/offeree

Takeda Pharmaceutical CO LTD

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

(e) Date position held/dealing undertaken:

     For an opening position disclosure, state the latest practicable date prior to the disclosure

11/09/2018

(f)  In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

     If it is a cash offer or possible cash offer, state "N/A"

YES: Shire PLC

 

                                                                                                                    

2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ordinary

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

2,673,803

0.34

6,183,350

0.79

(2) Cash-settled derivatives:

 

5,259,342

0.67

2,026

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

121,500

0.02

0

0.00

 

     TOTAL:

8,054,645

1.03

6,185,376

0.79

           

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b)        Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

 

3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a)        Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

JPY

Ordinary

Purchase

6,700

4600

Ordinary

Purchase

100

4585

Ordinary

Purchase

100

4563

Ordinary

Purchase

27,900

4600

Ordinary

Purchase

300

4552

Ordinary

Purchase

400

4526

Ordinary

Purchase

300

4526

Ordinary

Purchase

200

4478

Ordinary

Purchase

200

4545

Ordinary

Purchase

300

4544

Ordinary

Purchase

200

4544

Ordinary

Purchase

100

4573

Ordinary

Purchase

100

4553

Ordinary

Purchase

800

4600

Ordinary

Purchase

2,200

4600

Ordinary

Purchase

100

4537

Ordinary

Purchase

200

4528

Ordinary

Purchase

700

4529

Ordinary

Purchase

1,500

4511

Ordinary

Purchase

100

4478

Ordinary

Purchase

1,300

4483

Ordinary

Purchase

1,000

4548

Ordinary

Purchase

200

4578

Ordinary

Purchase

1,000

4584

Ordinary

Purchase

1,000

4553

Ordinary

Purchase

100

4547

Ordinary

Purchase

1,000

4580

Ordinary

Purchase

400

4549

Ordinary

Purchase

1,000

4536

Ordinary

Purchase

200

4579

Ordinary

Purchase

1,000

4590

Ordinary

Purchase

500

4554

Ordinary

Purchase

2,000

4517

Ordinary

Purchase

200

4550

Ordinary

Purchase

600

4589

Ordinary

Purchase

1,000

4553

Ordinary

Purchase

500

4537

Ordinary

Purchase

700

4585

Ordinary

Purchase

1,000

4552

Ordinary

Purchase

1,000

4586

Ordinary

Purchase

1,000

4602

Ordinary

Purchase

1,000

4554

Ordinary

Purchase

900

4474

Ordinary

Purchase

1,000

4590

Ordinary

Purchase

100

4503

Ordinary

Purchase

1,000

4500

Ordinary

Purchase

500

4498

Ordinary

Purchase

1,000

4586

Ordinary

Purchase

1,000

4491

Ordinary

Purchase

600

4493

Ordinary

Purchase

900

4536

Ordinary

Purchase

100

4585

Ordinary

Purchase

1,000

4580

Ordinary

Purchase

1,000

4585

Ordinary

Purchase

1,000

4548

Ordinary

Purchase

1,000

4561

Ordinary

Purchase

300

4495

Ordinary

Purchase

200

4598

Ordinary

Purchase

1,000

4599

Ordinary

Purchase

600

4563

Ordinary

Purchase

500

4481

Ordinary

Purchase

1,000

4478

Ordinary

Purchase

1,000

4547

Ordinary

Purchase

1,000

4478

Ordinary

Purchase

1,000

4494

Ordinary

Purchase

500

4542

Ordinary

Purchase

200

4550

Ordinary

Purchase

500

4495

Ordinary

Purchase

1,800

4496

Ordinary

Purchase

300

4551

Ordinary

Purchase

1,000

4552

Ordinary

Purchase

1,000

4585

Ordinary

Purchase

1,000

4524

Ordinary

Purchase

2,000

4583

Ordinary

Purchase

1,000

4507

Ordinary

Purchase

1,000

4575

Ordinary

Purchase

10,200

4600

Ordinary

Purchase

174

4433

Ordinary

Purchase

100

4585

Ordinary

Sale

1,000

4552

Ordinary

Sale

300

4548

Ordinary

Sale

27,000

4469

Ordinary

Sale

1,200

4599

Ordinary

Sale

100

4581

Ordinary

Sale

1,400

4512

Ordinary

Sale

200

4511.5

Ordinary

Sale

1,300

4511.5

Ordinary

Sale

1,300

4520.5

Ordinary

Sale

900

4526.5

Ordinary

Sale

100

4487

Ordinary

Sale

300

4553

Ordinary

Sale

1,300

4492

Ordinary

Sale

1,000

4552

Ordinary

Sale

200

4591

Ordinary

Sale

500

4595

Ordinary

Sale

1,400

4586

Ordinary

Sale

1,500

4588

Ordinary

Sale

100

4600

Ordinary

Sale

400

4602

Ordinary

Sale

200

4591

Ordinary

Sale

2,000

4591

Ordinary

Sale

2,200

4586

Ordinary

Sale

2,100

4574

Ordinary

Sale

1,200

4552

Ordinary

Sale

1,200

4463

Ordinary

Sale

2,400

4469

Ordinary

Sale

2,200

4535

Ordinary

Sale

200

4455

Ordinary

Sale

100

4474

Ordinary

Sale

500

4471

Ordinary

Sale

2,100

4552

Ordinary

Sale

100

4475

Ordinary

Sale

400

4477

Ordinary

Sale

2,400

4476

Ordinary

Sale

1,200

4479

Ordinary

Sale

700

4583

Ordinary

Sale

300

4495

Ordinary

Sale

100

4508

Ordinary

Sale

400

4504

Ordinary

Sale

300

4503

Ordinary

Sale

2,200

4583

Ordinary

Sale

2,200

4574

Ordinary

Sale

100

4499

Ordinary

Sale

500

4498

Ordinary

Sale

100

4493

Ordinary

Sale

200

4586

Ordinary

Sale

200

4585

Ordinary

Sale

400

4486

Ordinary

Sale

1,300

4494

Ordinary

Sale

1,000

4493

Ordinary

Sale

300

4542

Ordinary

Sale

200

4492

Ordinary

Sale

100

4552

Ordinary

Sale

200

4587

Ordinary

Sale

100

4587

Ordinary

Sale

1,200

4546

Ordinary

Sale

500

4586

Ordinary

Sale

1,000

4585

Ordinary

Sale

1,200

4595

Ordinary

Sale

1,500

4600

Ordinary

Sale

5,900

4600

Ordinary

Sale

24,000

4600

Ordinary

Sale

6,700

4600

Ordinary

Sale

48,000

4600

Ordinary

Sale

100

4459

Ordinary

Sale

200

4462

Ordinary

Sale

600

4456

Ordinary

Sale

3,100

4469

Ordinary

Sale

174

4374

Ordinary

Sale

100

4585

Ordinary

Sale

100

4585

 

Total Purchases

98,674

 

 

Total Sales

167,274

 

 

(b)        Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit JPY

 

 

 

 

 

 

 (c)       Stock-settled derivative transactions (including options)

 

(i)         Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit JPY

 

 

 

 

 

 

 

 

 

(ii)        Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit JPY

 

 

 

 

 

 

 

(d)        Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable) JPY

 

 

 

 

 

4.         OTHER INFORMATION

 

(a)        Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b)        Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i)  the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(c)        Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

YES

 

 

Date of disclosure:

12/09/2018

Contact name:

Olivier Vero

Telephone number:

+44 20 7676 6969

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk

 

 

 

 

 

                                                               SUPPLEMENTAL FORM 8 (OPEN POSITIONS)

 

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.

Note 5(i) on Rule 8 of the Takeover Code (the "Code")

 

 

1.         KEY INFORMATION

 

Full name of person making disclosure:

SOCIETE GENERALE SA

Name of offeror/offeree in relation to whose relevant securities the disclosure relates:

Takeda Pharmaceutical CO LTD

 

2.         STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

 

 

Class of relevant security

Product description e.g. call option

Written or purchased

Number of securities to which option or derivative relates

Exercise price per unit

Type

Expiry date

JPY

e.g. American, European etc.

Ordinary

OTC put-option

Sale

15,700

4707

European options

14/12/2018

Ordinary

OTC put-option

Sale

30,000

5075.10

European options

14/12/2018

Ordinary

OTC put-option

Sale

29,600

5073.65

European options

14/12/2018

Ordinary

OTC put-option

Sale

15,500

4491.40

European options

14/12/2018

Ordinary

OTC put-option

Sale

30,700

4533.90

European options

14/12/2018

 

 

 

3.         AGREEMENTS TO PURCHASE OR SELL ETC.

 

Full details should be given so that the nature of the interest or position can be fully understood:

 

 

 

 

 

 

It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.

 

The currency of all prices and other monetary amounts should be stated.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RETGGUPUBUPRGPP

Recent news on Takeda Pharmaceutical Co

See all news